Hendrik W. Reesink
Research Subjects
Hendrik W. Reesink has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
Stefan Zeuzem
J.W. Goethe University Hospital, Frankfurt, Germany
5 shared publicationsAndre van Vliet
PRA International, Zuidlaren, The Netherlands
3 shared publicationsChristine J. Weegink
3 shared publicationsFemke Stelma
Dep. of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands; Dep. of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands
3 shared publications- Alicja Wiercińska-Drapało
Department of Infectious and Tropical Diseases and Hepatology, Medical University of Warsaw, 01-201 Warsaw, Poland
2 shared publications - Janke Schinkel
Univ Amsterdam, Dept Med Microbiol, Amsterdam UMC, Amsterdam, Netherlands
2 shared publications
Latest Publications
- 1 April 2018
- Published by Elsevier in Journal of Hepatology
- Vol. 68, S757-S759
Incidence of hepatitis E infection in renal transplant patients in The Netherlands
- 1 April 2018
- Published by Elsevier in Journal of Hepatology
- Vol. 68, S757-S759
Incidence of hepatitis E infection in renal transplant patients in The Netherlands
- Open Access
- 1 October 2017
- Published by Elsevier in Antiviral Research
- Vol. 146, 139-145
Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing
- 1 October 2017
- Published by Elsevier in Antiviral Research
- Vol. 146, 139-145
Open AccessImmune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing
- 1 February 2017
- Published by Elsevier in The Lancet
- Vol. 389 (10070) , 709-717
Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial
- 1 February 2017
- Published by Elsevier in The Lancet
- Vol. 389 (10070) , 709-717
Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial
- 19 January 2017
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 2 (3) , 147-148
Peginterferon add-on: an added benefit?
- 19 January 2017
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 2 (3) , 147-148
Peginterferon add-on: an added benefit?
- 1 July 2015
- Published by Elsevier in Journal of Virological Methods
- Vol. 219, 28-37
A comparison of 454 sequencing and clonal sequencing for the characterization of hepatitis C virus NS3 variants
- 1 July 2015
- Published by Elsevier in Journal of Virological Methods
- Vol. 219, 28-37
A comparison of 454 sequencing and clonal sequencing for the characterization of hepatitis C virus NS3 variants
- 1 November 2014
- Published by Elsevier in Antiviral Research
- Vol. 111, 53-59
Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients
- 1 November 2014
- Published by Elsevier in Antiviral Research
- Vol. 111, 53-59
Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients
- 1 May 2012
- Published by SAGE Publications in Antiviral Therapy
- Vol. 17 (4) , 633-642
Rapid Decline of Viral RNA in Chronic Hepatitis C Patients Treated Once Daily with IDX320: A Novel Macrocyclic HCV Protease Inhibitor
Background: The addition of direct-acting antivirals to pegylated interferon-α plus ribavirin for the treatment of chronic HCV infection can result in an increased sustained viral response rate and may permit reduction in treatment duration. IDX320 is a potent non-covalent macrocyclic inhibitor of the HCV NS3/4A protease. Methods: This was a randomized double-blind placebo-controlled single- and multiple-dose study to assess the safety, tolerability, antiviral activity and pharmacokinetics of IDX320 in healthy volunteers (HV) and patients with chronic HCV genotype 1 infection. HV ( n=48) received single or multiple ascending doses of IDX320. Two HCV-infected patients received a single dose of 200 mg IDX320. Dosages for other HCV-infected patients were as follows: placebo, 50, 100, 200 or 400 mg of IDX320 orally once daily for 3 days ( n=30) or placebo/200 mg of IDX320 twice-daily for 3 days ( n=8). Results: In total, 48 HV and 40 HCV-infected patients were enrolled and all completed the study. There were no serious adverse events. The majority of adverse events were of mild or moderate intensity. Pharmacokinetics supported a once-daily dosing regimen. A rapid decline in plasma HCV RNA was observed in all patients. In the multiple-dose study, mean HCV RNA reductions were 2.6, 3.1, 3.1, 3.3 and 3.8 log 10 IU/ml after 3 days in the IDX320 50, 100, 200, 400 mg once-daily and 200 mg twice-daily treatment groups, respectively. This compared to a mean HCV RNA reduction of 0.04 log 10 in the placebo group. Conclusions: Once-daily IDX320 dosing demonstrated potent dose-dependent antiviral activity in treatment-naive HCV genotype-1-infected patients.
- 1 May 2012
- Published by SAGE Publications in Antiviral Therapy
- Vol. 17 (4) , 633-642
Rapid Decline of Viral RNA in Chronic Hepatitis C Patients Treated Once Daily with IDX320: A Novel Macrocyclic HCV Protease Inhibitor
Background: The addition of direct-acting antivirals to pegylated interferon-α plus ribavirin for the treatment of chronic HCV infection can result in an increased sustained viral response rate and may permit reduction in treatment duration. IDX320 is a potent non-covalent macrocyclic inhibitor of the HCV NS3/4A protease. Methods: This was a randomized double-blind placebo-controlled single- and multiple-dose study to assess the safety, tolerability, antiviral activity and pharmacokinetics of IDX320 in healthy volunteers (HV) and patients with chronic HCV genotype 1 infection. HV ( n=48) received single or multiple ascending doses of IDX320. Two HCV-infected patients received a single dose of 200 mg IDX320. Dosages for other HCV-infected patients were as follows: placebo, 50, 100, 200 or 400 mg of IDX320 orally once daily for 3 days ( n=30) or placebo/200 mg of IDX320 twice-daily for 3 days ( n=8). Results: In total, 48 HV and 40 HCV-infected patients were enrolled and all completed the study. There were no serious adverse events. The majority of adverse events were of mild or moderate intensity. Pharmacokinetics supported a once-daily dosing regimen. A rapid decline in plasma HCV RNA was observed in all patients. In the multiple-dose study, mean HCV RNA reductions were 2.6, 3.1, 3.1, 3.3 and 3.8 log 10 IU/ml after 3 days in the IDX320 50, 100, 200, 400 mg once-daily and 200 mg twice-daily treatment groups, respectively. This compared to a mean HCV RNA reduction of 0.04 log 10 in the placebo group. Conclusions: Once-daily IDX320 dosing demonstrated potent dose-dependent antiviral activity in treatment-naive HCV genotype-1-infected patients.
- 5 August 2011
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 46 (11) , 1362-1368
HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a
Background. The extensive heterogeneity of the hypervariable region-1 (HVR-1) of hepatitis C virus (HCV) evidences the high genetic flexibility of HCV and was shown to be associated with virologic response to interferon-α-based therapies. However, the evolution of HVR-1 heterogeneity during treatment with directly acting antivirals has not been studied. Methods. Clonal sequence analysis of HVR-1 quasispecies in the serum of patients who were treated with telaprevir (3 × 750 mg/day) alone, telaprevir plus pegylated interferon-α-2a (pegIFN-α-2a), or pegIFN-α-2a plus placebo for 14 days was performed. HVR-1 heterogeneity, expressed as Shannon complexity and Hamming distance, was analyzed with virologic response and with the emergence of variants associated with resistance to telaprevir. Results. HVR-1 heterogeneity at baseline was not associated with response to telaprevir-based therapy (Shannon complexity 0.34 vs. 0.55, p = 0.38; Hamming distance 0.15 vs. 0.23, p = 0.51; for patients with or without viral breakthrough, respectively). No significant changes in HVR-1 complexity were observed from baseline to day 4 of therapy in patients in whom a continued decline in HCV RNA was observed (Shannon complexity = 0.55 vs. 0.51, p = 0.67; Hamming distance = 0.23 vs. 0.25, p = 0.81, respectively). This was similar in patients with viral breakthrough associated with telaprevir-resistant variants (Shannon complexity = 0.34 vs. 0.42, p = 0.68; Hamming distance = 0.15 vs. 0.2, p = 0.50, at baseline and day 4, respectively). Conclusions. Baseline and on-treatment HVR-1 heterogeneity are not associated with early viral response to telaprevir-based therapy.
- 5 August 2011
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 46 (11) , 1362-1368
HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a
Background. The extensive heterogeneity of the hypervariable region-1 (HVR-1) of hepatitis C virus (HCV) evidences the high genetic flexibility of HCV and was shown to be associated with virologic response to interferon-α-based therapies. However, the evolution of HVR-1 heterogeneity during treatment with directly acting antivirals has not been studied. Methods. Clonal sequence analysis of HVR-1 quasispecies in the serum of patients who were treated with telaprevir (3 × 750 mg/day) alone, telaprevir plus pegylated interferon-α-2a (pegIFN-α-2a), or pegIFN-α-2a plus placebo for 14 days was performed. HVR-1 heterogeneity, expressed as Shannon complexity and Hamming distance, was analyzed with virologic response and with the emergence of variants associated with resistance to telaprevir. Results. HVR-1 heterogeneity at baseline was not associated with response to telaprevir-based therapy (Shannon complexity 0.34 vs. 0.55, p = 0.38; Hamming distance 0.15 vs. 0.23, p = 0.51; for patients with or without viral breakthrough, respectively). No significant changes in HVR-1 complexity were observed from baseline to day 4 of therapy in patients in whom a continued decline in HCV RNA was observed (Shannon complexity = 0.55 vs. 0.51, p = 0.67; Hamming distance = 0.23 vs. 0.25, p = 0.81, respectively). This was similar in patients with viral breakthrough associated with telaprevir-resistant variants (Shannon complexity = 0.34 vs. 0.42, p = 0.68; Hamming distance = 0.15 vs. 0.2, p = 0.50, at baseline and day 4, respectively). Conclusions. Baseline and on-treatment HVR-1 heterogeneity are not associated with early viral response to telaprevir-based therapy.
- 1 March 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (3) , 913-921
Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients
- 1 March 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (3) , 913-921
Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5) , A-116-116
751d SVR Results of Prove3, a Phase 2B Clinical Trial Assessing Safety and Efficacy of Telaprevir in Hepatitis C Genotype-1-Infected Patients with Prior Non-Response, Viral Breakthrough or Relapse to Peginterferon-Alfa-2a/B and Ribavirin Therapy
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5) , A-116-116
751d SVR Results of Prove3, a Phase 2B Clinical Trial Assessing Safety and Efficacy of Telaprevir in Hepatitis C Genotype-1-Infected Patients with Prior Non-Response, Viral Breakthrough or Relapse to Peginterferon-Alfa-2a/B and Ribavirin Therapy